
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is poised to see strong sales growth as it laps headwinds from process chromatography in 2027 and implements a meaningful restructuring program that aims to improve margins. The company's ownership stake in Sartorius, which is set to increase in value once the controlling Trust terminates in mid-2028, adds potential upside to its stock. While Bio-Rad's sustainability integration is limited, its core business aligned with positive health outcomes, and the company has announced sustainability goals.
Bears say
Bio-Rad Laboratories is a diversified company with a majority of its revenue coming from the clinical diagnostics market and the rest from the life sciences market. However, multiple factors such as a potential loss of confidence in the company's sales and margin trajectory and a potential decrease in the value of its stake in Sartorius could lead to further multiple erosion and a lower stock price. This potential downside scenario is exacerbated by risks such as a longer-than-expected recovery in end markets, continued share losses in ddPCR, and uncertainties surrounding the company's M&A strategy and the potential impact of AI on the life sciences industry. Additionally, the company's corporate governance structure, with a single family controlling a majority of the voting power, could create further uncertainty in the company's direction and may not align with other shareholders.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares